# Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

> **NCT04352166** · PHASE2 · SUSPENDED · sponsor: **Frances R Levin** · enrollment: 40 (estimated)

## Conditions studied

- Opioid-use Disorder

## Interventions

- **DRUG:** extended-release buprenorphine (BXR)
- **DRUG:** sublingual buprenorphine (BSL)

## Key facts

- **NCT ID:** NCT04352166
- **Lead sponsor:** Frances R Levin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-12-15
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. This study will resume recruitment after OHRP has approved the resumption of research.
- **Last updated:** 2025-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04352166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04352166, "Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04352166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*